Koffiekamer « Terug naar discussie overzicht

Nanobiotix met haar NBTXR3 richting €80,- in 2014 ? (Heden €17,-)

524 Posts, Pagina: « 1 2 3 4 5 6 ... 16 17 18 19 20 21 22 23 24 25 26 27 » | Laatste

Omlaag ↓

[verwijderd] 10 november 2014 12:24

Nanobiotix : Gilbert Dupont conforté dans son opinion positive

(Tradingsat.com) - Gilbert Dupont a réitéré lundi sa recommandation "Acheter" et son objectif de cours de 23 euros sur Nanobiotix. Le courtier fait une lecture croisée positive de la récente signature par le groupe pharmaceutique Merck d'un accord avec la société Bind Therapeutics, spécialisée en nano-médecine.

Alors qu' "un grand nombre de big pharmas souffr[e]nt de la perte (passée ou future) d’exclusivité de certains brevets", Gilbert Dupont note que ces grands groupes pharmaceutiques s'intéressent particulièrement aux projets basés sur une amélioration du rapport risque / efficacité de thérapie existantes. Or "c’est l’objectif de NanoBiotix, mais pour la radiothérapie", note le broker.

A lire aussi
Créez et gérez votre portefeuille virtuel
Pour mémoire, la technologie NanoXray de Nanobiotix utilise des nanoparticules constituées de matériaux dont les propriétés physico-chimiques leur permettent d’absorber les rayons X. L’injection au préalable de ces nanoparticules dans les tumeurs des patients dans le cadre d’une séance de radiothérapie normale, permet d’augmenter l’absorption des rayons X et devrait permettre d’augmenter l’efficacité du traitement.

www.tradingsat.com/nanobiotix-FR00113...

Laugh about it 10 november 2014 16:53

Positief vanuit Gilbert, dank voor plaatsen Bakker! Het doorbreken van de 20-er grens had ik al verwacht.., wachten is op passeren van deze horde.

Ferdinand 62 11 november 2014 14:36

Is er nieuws?? Ik kan niets vinden, maar het gaat in ieder geval erg hard.

Ferdinand 62 12 november 2014 10:48

Er staat iets te gebeuren. Nu 20000 stuks in de laat. Afgelopen maandag voor opening ook al bijna 30000 stuks voor opening in de laat en vlak voor de opening werden ze er allemaal uitgehaald. Ik verwacht goed nieuws op heel korte termijn en denk dat er nog een partij goedkoop in wil kopen. Ik kan me niet voorstellen dat je er anders in een alsmaar stijgende trend zoveel tegelijk in de laat zet.

[verwijderd] 12 november 2014 11:04

quote:
Ferdinand 62 schreef op 12 november 2014 10:48:
Er staat iets te gebeuren. Nu 20000 stuks in de laat. Afgelopen maandag voor opening ook al bijna 30000 stuks voor opening in de laat en vlak voor de opening werden ze er allemaal uitgehaald. Ik verwacht goed nieuws op heel korte termijn en denk dat er nog een partij goedkoop in wil kopen. Ik kan me niet voorstellen dat je er anders in een alsmaar stijgende trend zoveel tegelijk in de laat zet.

Ja, dat is een aardig block.

[verwijderd] 12 november 2014 11:13

quote:
bakker1628 schreef op 12 november 2014 11:04:
[...]

Ja, dat is een aardig block.

Block is 10 minuten helemaal opgegeten.

Ferdinand 62 12 november 2014 11:25

Wel bijzonder, zo snel. Nu kijken of we verder omhoog kunnen.

[verwijderd] 14 november 2014 15:05

Kom op Nano

Ferdinand 62 26 november 2014 09:04

Nanobiotix geeft 650.000 aandelen uit in private placement aan een Amerikaanse investeerder voor € 15,99 per aandeel. Zie website Nanobiotix. Op het eerste gezicht altijd ongunstig, maar meestal bij Bio juist positief Ze halen ruim 10 miljoen euro op en dit kan via warrants oplopen tot ruim 14 miljoen. Hiermee is het mogelijk om alles verder te ontwikkelen. Ik denk dat het op korte termijn wel eens een boost aan de koers kan geven.

[verwijderd] 26 november 2014 11:07

quote:
Ferdinand 62 schreef op 26 november 2014 09:04:
Nanobiotix geeft 650.000 aandelen uit in private placement aan een Amerikaanse investeerder voor € 15,99 per aandeel. Zie website Nanobiotix. Op het eerste gezicht altijd ongunstig, maar meestal bij Bio juist positief Ze halen ruim 10 miljoen euro op en dit kan via warrants oplopen tot ruim 14 miljoen. Hiermee is het mogelijk om alles verder te ontwikkelen. Ik denk dat het op korte termijn wel eens een boost aan de koers kan geven.

Een boost is : de 30 toucheren.
Maar dat lijkt nog lang niet in zicht.
Zou het überhaupt ooit zover komen.....

Stif 28 november 2014 19:21

Ik zit er weer in met 1000 aandelen. Op korte termijn veel nieuws verwacht.

- Voor het einde van 2014: Resultaten tussenfase piloot NBTXR3 hoofd-en halskanker
- Voor het einde van 2014: het evalueren van alternatieven, waaronder een samenwerking met een farmaceutische Amerikaanse acteur aan de ontwikkeling en commercialisering van NBTXR3 zorgen
- Voor het einde van 2014: afronding van de preklinische fase NBTX-TOPO (Goederen NBTX-TOPO is een gel met nanodeeltjes, die streven naar direct worden toegepast in de 'tumor bed "in de uitkomst van een chirurgische ingreep voor het verwijderen van tumor, om voor te bereiden voor postoperatieve radiotherapie om eventuele resterende kankercellen te vernietigen).
- Late 2014: Start weke delen sarcoom NBTXR3 cruciale fase. Het zal 10 tot 12 Europese landen en tussen 100 en 200 patiënten omvatten.
- Early 2015: vroege testfase, pivot leverkanker waarbij 200 400 mensen (eindigt in de late 2017)
- 2016: resultaten stadium weke delen sarcoom spil
- Late 2016: CE NBTXR3 en marketing
- 2015 Results spil stadium hoofd-en halskanker

[verwijderd] 3 december 2014 08:05

Nanobiotix valuation hiked following injection of new funds

City broker Oriel Securities hiked its valuation of Nanobiotix (EPA:NANO) following a fundraise that will allow it to expand its current research base as well as initiating a US clinical programme.
The potential positive impact of this push into America prompted the change in ‘fair value’ of the stock, which rises to €25.50 from €23 previously.
The shares are currently changing hands for €17.73, valuing the business at €238mln.
Last week Nanobiotix completed a stock placing with Capital Ventures International will raise an initial €10.4mln, while the warrants attached to the shares could bring in a further €14.1mln between now and June 2016.
There may also be the opportunity to sell an additional €10mln tranche of equity between November next year and March 2016.
Nanobiotix has developed NBTXR3, a liquid containing nano-particles injected into the tumour that allows radiotherapy to be administered in a very targeted and effective way.
The new treatment is able to destroy more of the tumour, improving the quality of surgery that follows the course of treatment, thus enabling a more complete removal of the cancer.
It is currently being tested in cancers found in muscle or fat - a condition called soft tissue sarcoma (STS).
The clinical development plan for Europe and the US now includes a larger number of therapeutic indications, including head and neck, liver and prostate cancers.
Interestingly, Nanobiotix has opted to push into pivotal trials under its own steam in the States rather than partnering as it has in Asia.
This way it can retain much more of the value it creates in the world’s largest healthcare market.
Oriel said a US pilot study of NBTXR3 in the treatment of prostate cancer is planned for the second half of next year, with results possible in the first half of 2017.
“We continue to believe that the main driver of investor sentiment will be the results from the pivotal soft tissue sarcoma trial, which will run until the end of 2016,” said Oriel analyst Michael King.

www.proactiveinvestors.co.uk/companie...

[verwijderd] 3 december 2014 08:06

Nanobiotix makes funding breakthrough; will go it alone in the US

Nanobiotix (EPA:NANO) is receiving a significant cash injection that will bankroll the further development of its ground-breaking advance on radiotherapy as well funding its push unpartnered into the US.
The stock placing with Capital Ventures International will raise an initial €10.4mln, while the warrants attached to the shares could bring in a further €14.1mln between now and June 2016.
There may also be the opportunity to sell an additional €10mln tranche of Nanobiotix equity between November next year and March 2016.
The cash will be used to broaden the potential applications for NBTXR3, which is currently being tested in cancers found in muscle or fat - a condition called soft tissue sarcoma.
NBTXR3 is a liquid containing nano-particles injected into the tumour that allows radiotherapy to be administered in a very targeted and effective way.
The new treatment is able to destroy more of the tumour, improving the quality of surgery that follows the course of treatment, thus enabling a more complete removal of the cancer.
The clinical development plan for Europe and the US now includes a larger number of therapeutic indications, including head and neck, liver and prostate cancers.
Interestingly, Nanobiotix has opted to push into pivotal trials under its own steam in the States rather than partnering as it has in Asia.
This way it can retain much more of the value it creates in the world’s largest healthcare market.
“We also see that the broadening of the therapeutic indications provides multiple opportunities for our nano-medicine approach which has significant potential to change the way cancer is treated,” said chief executive Laurent Levy.
“The substantial investment from Capital Ventures International, a large and recognised US investor, supports this ambitious business strategy, and further strengthens and internationalises our shareholder base. This is a major step for our future growth.”

The shares, up 230% in the year to date, closed flat at €17.61.

www.proactiveinvestors.co.uk/companie...

[verwijderd] 4 december 2014 11:24

Edison herziet haar waardering naar potentieel van 33 euro per aandeel.

www.edisoninvestmentresearch.com/rese...

Ferdinand 62 10 december 2014 18:11

Edison herziet haar waardering naar potentieel van 33 euro per aandeel.

www.edisoninvestmentresearch.com/rese...

Alleen maar positief nieuws geweest en de koers gaat maar verder terug. Wel weer een mooi instapmoment nu gesloten op € 16,36 als Edison gelijk krijgt binnen een jaar wat volgens mij mogelijk moet zijn dan valt er aardig wat mee te verdienen. Eerst nog maar wat goed nieuws om de koers omhoog te krijgen.

[verwijderd] 11 december 2014 21:40

Op het Franse forum is de paniek groot, zag net al een koersdoel van 11 euro langs komen.
Momenteel is er geen lol aan, denk dat er aankomende maanden ook geen nieuws zal komen. Hoofd en nek resultaten zijn uitgesteld.
Hopelijk zakken we niet in dit tempo door want het gaat nu wel weer erg hard.

[verwijderd] 7 januari 2015 08:54

Financiële kalender 2015 :

27 februari 2015: De omzet voor het vierde kwartaal 2014
30 april 2015: Jaarcijfers 2014
15 mei 2015: De omzet voor het 1 e kwartaal 2015
15 juli 2015: De verkoop van de 2 e kwartaal 2015
31 augustus 2015: Halfjaarresultaten 2015
13 november 2015: De omzet van 3 e kwartaal 2015
Vóór 30 juni 2015: Jaarlijkse Algemene Vergadering

[verwijderd] 8 januari 2015 12:45

Nanobiotix on its way to change the paradigm in cancer therapy

Nanobiotix is an oncology focused nanomedicine company developing an innovative nanoparticle technology. Their NanoXray technology comprises three products having the potential to cause a paradigm shift in cancer therapy. NanoXray products are developed to selectively increase the efficacy of radiotherapy in the tumor cell.

The following video is showing how this disruptive technology is acting in the patient’s body.

The Company made major clinical and financial progress, including broadening of indications and strategic plans across Europe, Asia and the US.

NBTXR3 flagship of the clinical development

The company is developing three different products that can be administered either by direct injection into the tumor (NBTXR3), intravenous injection (NBTX-IV) or topical application to fill tumor cavities just after tumor surgery (NBTX-TOPO). NBTXR3 is the first product of the NanoXray portfolio to reach clinical development. The product comprises nanoparticles which can be injected directly into tumor. With the application of radiotherapy, these nanoparticles absorb X-rays which significantly enhances the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues. Currently, NBTXR3 is classified as a medical device in Europe and a drug in the United States (US).

In June 2014, the Company presented positive Phase I clinical study results for NBTXR3, demonstrating feasibility and safety of intratumoral injection of the product followed by radiotherapy in patients with locally advanced STS. In addition to the feasibility and safety data presented, promising signs of efficacy have been demonstrated. The positive results led the French National Security Agency for Medicines and Health Products (ANSM) to allow Nanobiotix to enter into a Phase II/III pivotal trial, which is the final step before registration (CE mark).

This study started end 2014 in France and will be broadened out to 25-30 sites in Europe once further authorizations are received. This international multi-center pivotal study is expected to be completed towards the end of 2016 with interim results in mid-2016.

In the Asia-Pacific region, Nanobiotix’s partner, PharmaEngine intends to participate in the pivotal study by opening clinical sites in several Asia-Pacific countries. In the US, depending on the interim clinical results, expected mid-2016, the Company will decide if doable to expand the development of NBTXR3 through a bridge study in this indication to access this market.

NBTXR3 is also in development for elderly patients with locally advanced head and neck cancer. The aim is the decrease of the tumor size and the preservation of the local functions. Nanobiotix is currently conducting a pilot trial for this indication, for which interim results are expected in H1 2015. In 2014, two new sites were opened in Spain for this pilot trial.

New Indications with High Potential: Liver Cancers and Prostate Cancer

Liver cancers are potentially the largest indication for NBTXR3. Nanobiotix is already pursuing the non-clinical evaluation phase of NBTXR3 in primary liver cancer, and as part of its expanded development plan, is also evaluating the compound in liver metastases (metastases arising from colorectal cancers, breast cancer, etc.). Nanobiotix plans to initiate clinical trials in this indication in the second half of 2015 and will include patient populations with both Primary liver cancer and liver metastases. For this patient population, the aim of treatment is to increase and prolong patients’ survival rates. This program is being supported with a €2.8m grant from Bpifrance through the NICE project..

The Company is also seeking to develop NBTXR3 for patients with high risk prostate cancer, with the aim of providing effective tumor control combined with tumor destruction. It represents a significant potential new market for the product. The planned pilot trial is expected to start in the second half of 2015 and will involve approximately 24-30 patients that are newly diagnosed with high risk prostate cancer.

NBTXR3 could be also developed in other indications as the potential is broad especially for esophagus cancer, glioblastoma, cervix cancer, etc.

So What’s next?

Nanobiotix is pursuing a standalone development and commercialization strategy for its lead product NBTXR3 in Europe. As part of the international strategy, in September, Nanobiotix opened an affiliate office in Cambridge, MA. In the Asia-Pacific region, Nanobiotix is already partnered with PharmaEngine. During 2014, the company completed two capital raises, totaling €38.5m, with the potential for another €24.1m.

Nanobiotix is in a strong financial position to pursue its standalone strategy in both Europe and US. In 2015, further clinical progress are expected and Nanobiotix is also preparing for the future by expanding its pipeline with two other NanoXray products (NBTX-TOPO and NBTX-IV) and beyond.

The way seems clear for Nanobiotix and the paradigm in cancer therapy could change in the future thanks to their innovation.

labiotech.eu/nanobiotix-way-change-pa...

[verwijderd] 9 januari 2015 12:37

Research report Edison, koersdoel 33,00 Euro

Bijlage:

[verwijderd] 28 januari 2015 08:31

Nanobiotix Shares Transferred from Compartment C to Compartment B of the Regulated Market of Euronext in Paris
Tue Jan 27, 2015 4:19pm EST

* Reuters is not responsible for the content in this press release.

Nanobiotix Shares Transferred from Compartment C to Compartment B of the Regulated Market of Euronext in Paris

Regulatory News:

NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces the transfer of its shares from compartment C to compartment B of the regulated market of Euronext in Paris with effect as from January 28, 2015, thanks to its stock market capitalization increase performances during 2014.

Compartment B groups together listed companies with a stock market capitalization of between 150 million and 1 billion euros. For the record, the average market capitalization of Nanobiotix over the last 60 trading days in 2014 was 249 million euros.

This transfer has no impact on the inclusion of Nanobiotix shares to NYSE Euronext indexes.

Laurent Levy, CEO of Nanobiotix comments: “Following our admission to the SRD label in December, we are proud to announce the transfer of our shares from compartment C to compartment B of the regulated market of Euronext in Paris. This transfer rewards the dynamism and stock market performance of Nanobiotix during 2014. This operation and the strong increase of Nanobiotix shares liquidity with more than 1 billion 300 million euros traded this year, should improve the visibility of Nanobiotix to the international financial and industrial communities.”

Compartment transfers were officially announced to market members by means of a notice to the market from Euronext on January 26, with an effective date of January 28, 2015.

Next financial press release: revenue for the 4th quarter of 2014 by February 27, 2015

524 Posts, Pagina: « 1 2 3 4 5 6 ... 16 17 18 19 20 21 22 23 24 25 26 27 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 910,90 -1,01 -0,11% 14:20


Germany40^	18.702,50	-0,21%
BEL 20	3.968,60	-0,30%
Europe50^	5.076,00	-0,06%
US30^	39.491,60	+0,11%
Nasd100^	18.211,10	+0,03%
US500^	5.226,38	+0,06%
Japan225^	38.303,80	+0,29%
Gold spot	2.347,21	+0,45%
EUR/USD	1,0799	+0,09%
WTI	78,29	-1,15%